Edit Module

Zoetis Earns License for Cytopoint Skin Therapy

The newly branded therapy, formally known as Canine Atopic Dermatitis Immunotherapeutic, is formulated to target and neutralize interleukin-31 (IL-31).


Published:

Zoetis

Apoquel, say hello to your baby brother Cytopoint.

Veterinary drug maker Zoetis Inc. in December received a U.S. Department of Agriculture license for Cytopoint, which the Parsippany, N.J., company described as the first monoclonal antibody (mAb) therapy approved “to help provide sustained control of the clinical signs associated with atopic dermatitis in dogs.”

If the indication sounds familiar, it may be because Cytopoint earned a conditional license in August 2015, when it was known as Canine Atopic Dermatitis Immunotherapeutic. Cytopoint is injected every four to eight weeks.

The newly branded therapy is formulated to target and neutralize interleukin-31 (IL-31). The atopic dermatitis drug Apoquel (oclacitinib tablet) is designed to quickly rid dogs of the urge to itch.

Edit Module
Edit ModuleShow Tags

Archive »Read More

Study: Number of Dogs in Shelters at All-Time Low?

Results from a study from Michigan State University College of Veterinary Medicine gives a better estimate about how many dogs are being taken in by shelters, adopted out, transferred and euthanized.

VIN Foundation Launches Student Debt Center

This interactive resource provides information and tools to help students navigate their vet school debt.

"One Lucky Dog:" Vet Treats Dog Who Was Shot in Head

A 9-month-old Great Pyrenees named Nylah went missing and then was later found with a bullet wound in her head.
Edit Module
Edit Module
Edit ModuleEdit ModuleShow Tags Edit Module
Edit Module Edit Module
Edit ModuleShow Tags

Events


Show More...
Edit Module
Edit Module